Nevertheless, cetuximab has limited efficacy as a single agent,8 and subsequent trials evaluating alternative EGFR inhibitors (including afatinib, panitumumab, and zalutumumab) have all shown similarly modest responses in HNSCC.9, 10, 11. Here, EGFR is linked to head and neck squamous cell carcinoma.